Riskpilot← Back to searchSign inGet full accessReTaMed ApS
APSActiveCVR 39608405Nygårdsvej 73Business and other management consultancy activities · NACE 7020Est. 20181 employees
Revenue 2024
DKK 0
EBITDA margin
—
Equity ratio
45.1%
Financial strength
Net profit 2024
DKK -861
+89% vs 2023
| Revenue | DKK 0 | — |
| EBITDA | DKK 0 | — |
| Net profit | DKK -861 | +89% |
| Total assets | DKK 223K | -10% |
| Equity | DKK 101K | +0% |
| Employees | 1 | — |
Legal name
ReTaMed ApS
CVR number
39608405
Legal form
Anpartsselskab
NACE code
7020 · Business and other management consultancy activities
Founded
20. maj 2018
Share capital
DKK 50.000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktionen.
Company purpose
Selskabets formål er at drive virksomhed med konsulentvirksomhed og hermed forbundet virksomhed efter ledelsens skøn. Dertil er formålet at importere, producere, forhandle og eksportere lægemidler samt hermed forbundet virksomhed efter ledelsens skøn.
Address
Nygårdsvej 73
Phone
+4521613520
Email
hvknudsen@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 350 | -60 | -18 | -14 | 0 |
| Staff expenses | -399 | -0 | -0 | -0 | -0 |
| EBITDA | -206 | -61 | -18 | -14 | 0 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -206 | -61 | -18 | -14 | 0 |
| Net financials | 4 | 4 | 5 | 6 | -1 |
| Profit before tax | -203 | -57 | -13 | -8 | -1 |
| Tax | 35 | -0 | -0 | -0 | -0 |
| Net profit | -238 | -57 | -13 | -8 | -1 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 323 | 225 | 256 | 248 | 223 |
| Equity | 178 | 121 | 108 | 101 | 101 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 145 | 104 | 147 | 147 | 122 |
| Total debt | 145 | 104 | 147 | 147 | 122 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20202024
Equity ratio
45.1%
This company
38.2%
Market median
+18% vs market
20202024
Return on equity
-0.9%
This company
18.4%
Market median
-105% vs market
20202024
Net profit margin
-86100.0%
This company
8.1%
Market median
-1063063% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
1.22×
This company
0.62×
Market median
-97% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HF Chief Executive Officer | Chief Executive Officer | 2018 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ReTaMed Holding ApS
ReTaMed ApS Board members of ReTaMed ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Henrik Fomsgaard-Knudsen | Chief Executive Officer | 0 companies |